Results 191 to 200 of about 1,590,116 (307)

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

A systematic review of the effect of personal health records on patient activation. [PDF]

Digit Health
Osovskaya I, Blandford A, Potts HW.
europepmc   +1 more source

Yoga4Health on social prescription: a mixed methods evaluation [PDF]

, 2019
Cartwright, T., Cartwright, T., Cheshire, A., Cheshire, A., Edwards, A., Edwards, A., Richards, R., Richards, R.   +7 more
core  

Dammarenediol II enhances etoposide‐induced apoptosis by targeting O‐GlcNAc transferase and Akt/GSK3β/mTOR signaling in liver cancer

Molecular Oncology, EarlyView.
Etoposide induces DNA damage, activating p53‐dependent apoptosis via caspase‐3/7, which cleaves PARP1. Dammarenediol II enhances this apoptotic pathway by suppressing O‐GlcNAc transferase activity, further decreasing O‐GlcNAcylation. The reduction in O‐GlcNAc levels boosts p53‐driven apoptosis and influences the Akt/GSK3β/mTOR signaling pathway ...
Jaehoon Lee, Byung‐Cheol Han, Gi‐Bang Koo, Jihye Park, Mijin Kwon, Young Bin Park, Jae‐Mun Choi, Seung‐Ho Lee, Sangho Roh   +8 more
wiley   +1 more source

Patient Activation and Shared Decision-Making Among Hispanics/Latinos With Metastatic Cancer: A Qualitative Study. [PDF]

Psychooncology
Meguro J, Khawand-Azoulai M, Medina HN, Pons M, Huber MT, Penedo FJ, Moreno PI.   +6 more
europepmc   +1 more source

Tumor mutational burden as a determinant of metastatic dissemination patterns

Molecular Oncology, EarlyView.
This study performed a comprehensive analysis of genomic data to elucidate whether metastasis in certain organs share genetic characteristics regardless of cancer type. No robust mutational patterns were identified across different metastatic locations and cancer types.
Eduardo Candeal, Andrea Moreno‐Manuel, Miguel Salvadó‐Pertierra, Cristina Santos‐Vivas, Rebeca Sanz‐Pamplona   +4 more
wiley   +1 more source

Exploring Patient Activation and Compliance in Patients with Different Rheumatological Disorders. [PDF]

Healthcare (Basel)
Almalag HM, Alosaimi N, Alqahtani R, Alharbi R, Alarfaj AS, Omair MA, Bedaiwi M, Qurtas I, Almaghlouth I, Alsabhan JF, Alsuwayni B, Juffali LA.   +11 more
europepmc   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

General practitioners' attitudes and barriers to patient activation in cardiovascular disease prevention: insights from the DECADE study. [PDF]

BMC Prim Care
Gräfe W, Tinsel I, Börger M, Kloppe T, Maun A, Riemenschneider H.   +5 more
europepmc   +1 more source

Mullins' syndrome: a new gammopathy-related autoinflammatory syndrome resistant to anakinra [PDF]

, 2015
A.L. Manson, Arend, Gekowski, H.J. Longhurst, Haeffner-Cavaillon, J.D. Cavenagh, M.S. Buckland, Nashan, Okusawa, P.F.K. Yong, Rybojad, S. Grigoriadou, Schindler   +12 more
core   +1 more source